Ascus Biosciences is a technology company.
Ascus Biosciences has raised $46.0M across 1 funding round.
Ascus Biosciences has raised $46.0M in total across 1 funding round.
# Ascus Biosciences: A Deep Dive
Ascus Biosciences (now operating as Native Microbials) is a biotechnology company that develops microbial-based solutions for animal health and nutrition[1][3]. The company uses computational and genomics-based technology platforms to discover and develop next-generation microbial products designed to improve animal outcomes across multiple species[2].
Founded in 2015 and headquartered in San Diego, California, the company serves the global animal agriculture and companion animal markets[3]. Its core mission is to improve the health and well-being of animals worldwide by delivering breakthrough microbial solutions grounded in the science of endomicrobial ecology[1]. Rather than relying on synthetic interventions, Native Microbials leverages naturally occurring microbes native to each animal species to achieve optimal health outcomes[1].
The company has demonstrated strong growth momentum, securing $46 million in Series B funding earlier in 2025, positioning it to expand its product pipeline and market reach[1].
Ascus Biosciences was founded in 2015 by Karsten Templin and is based in San Diego, California[3][5]. The company emerged from a recognition that animal health could be fundamentally improved through understanding and harnessing the microbial communities that naturally exist within and on animals.
The company's evolution culminated in a strategic rebranding to Native Microbials to better align its brand identity with its core technology approach and product pipeline[1]. This rebranding reflects the company's maturation from a research-stage biotech firm into a commercialization-focused organization preparing to launch its first products in the U.S. market. The timing of the rebrand coincided with the Series B funding round, signaling investor confidence and readiness for scaled market entry[1].
Ascus Biosciences operates at the intersection of biotechnology, computational biology, and agricultural innovation. The company is riding several converging trends:
Precision Animal Agriculture: The shift toward data-driven, science-based approaches to animal health mirrors broader precision agriculture trends. Rather than broad-spectrum antibiotics or chemical interventions, the industry is moving toward targeted, biology-aligned solutions[1].
Microbiome Science Maturation: As genomic sequencing costs have plummeted and microbiome research has accelerated, companies like Native Microbials can now leverage massive datasets to develop products that were previously impossible to create. The company's competitive moat is built on this data advantage[1].
Regulatory and Consumer Pressure: Growing concerns about antibiotic resistance, animal welfare, and sustainable food production create tailwinds for alternative solutions that improve animal health without synthetic interventions[1].
Venture Capital Interest in Deep Tech: The $46 million Series B funding reflects investor appetite for deep-science biotech companies solving real-world problems in large markets like animal agriculture[1].
Native Microbials is positioned to become a significant player in the animal health market by solving a fundamental problem—optimizing animal microbiomes—using cutting-edge science and proprietary data. The company's success will depend on three factors: (1) demonstrating clinical and commercial efficacy of Galaxis and Avius Protect in the U.S. market, (2) scaling manufacturing and distribution across multiple species and geographies, and (3) building brand recognition among veterinarians, producers, and feed companies.
The broader trend favoring biology-aligned, sustainable animal health solutions suggests strong tailwinds ahead. If Native Microbials executes on its pipeline and achieves market adoption, it could establish itself as a category leader in microbial-based animal health—a market likely to expand significantly as regulatory pressure on antibiotics intensifies globally. The company's deep science foundation and first-mover advantage in endomicrobial products position it well to capture this emerging opportunity.
Ascus Biosciences has raised $46.0M in total across 1 funding round.
Ascus Biosciences's investors include Builders VC.
Ascus Biosciences has raised $46.0M across 1 funding round. Most recently, it raised $46.0M Series B in May 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2020 | $46.0M Series B | Builders VC |